<- Go Home
Illumina, Inc.
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Market Cap
$12.1B
Volume
2.0M
Cash and Equivalents
$1.1B
EBITDA
$701.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$3.0B
Profit Margin
68.37%
52 Week High
$156.66
52 Week Low
$68.70
Dividend
N/A
Price / Book Value
5.12
Price / Earnings
-9.93
Price / Tangible Book Value
12.58
Enterprise Value
$13.5B
Enterprise Value / EBITDA
16.86
Operating Income
$347.0M
Return on Equity
30.13%
Return on Assets
2.64
Cash and Short Term Investments
$1.2B
Debt
$2.6B
Equity
$2.4B
Revenue
$4.4B
Unlevered FCF
$327.9M
Sector
Life Sciences Tools and Services
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium